Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30014144 | 0.89 | GABRD (0.45) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL27117336 | 0.86 | KMT2A (0.44) | L3MBTL3L3MBTL1CRBNDDB1NAMPT | |
| SCHEMBL31232873 | 0.84 | CRBN (0.52) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL27123682 | 0.81 | JAK1 (0.37) | CRBNDDB1NAMPT | |
| SCHEMBL30014459 | 0.80 | GABRD (0.46) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL24671839 | 0.77 | CRBN (0.49) | CRBNDDB1 | |
| SCHEMBL24670629 | 0.77 | CRBN (0.49) | CRBNDDB1 | |
| SCHEMBL24671836 | 0.77 | CRBN (0.49) | CRBNDDB1 | |
| SCHEMBL30731869 | 0.76 | DDB1 (0.45) | L3MBTL1CRBNDDB1 | |
| SCHEMBL30816878 | 0.76 | GABRD (0.42) | GABRDGABRA1GABRB1GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119907792-A | Benzyl or thiophene methylene substituted aminoquinazoline derivatives and their use as SOS1 degradants | 领泰生物医药(绍兴)有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-115232108-B | SOS1 degradation agent and preparation method and application thereof | 领泰生物医药(绍兴)有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20240261417-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| WO-2024083255-A1 | BENZYL OR THIENYLMETHYLENE-SUBSTITUTED AMINOQUINAZOLINE DERIVATIVE AND USE THEREOF AS SOS1 DEGRADATION AGENT | 上海领泰生物医药科技有限公司 | 2024-04-25 | — | — | WO | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| CN-115232114-B | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| WO-2022223039-A1 | SOS1 DEGRADER, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海领泰生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
| WO-2022223033-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海领泰生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
| WO-2022223034-A1 | SOS1 DEGRADATION AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海领泰生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
| CN-115232111-A | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115232114-A | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115232108-A | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SOS1, RAC1, RSU1 | GABRD 3578/4885GABRA1 3161/4885GABRB1 3546/4885 |
| US-20240261417-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | RAC1, SOS1, RSU1 | GABRD 2970/4885GABRA1 2754/4885GABRB1 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.